Regeneron Pharmaceuticals Inc. buy gerihouse
Start price
22.03.20
/
50%
€400.05
Target price
27.04.20
€535.00
Performance (%)
27.08%
End price
27.04.20
€508.40
Summary
This prediction ended on 27.04.20 with a price of €508.40. The prediction had a final performance of 27.08%. gerihouse has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.533% | 0.533% | 20.954% | -10.869% |
| iShares Core DAX® | -1.741% | 5.666% | 7.839% | 50.715% |
| iShares Nasdaq 100 | 2.815% | 11.547% | 36.610% | 102.822% |
| iShares Nikkei 225® | -0.109% | 9.654% | 45.650% | 64.795% |
| iShares S&P 500 | 0.966% | 7.240% | 26.969% | 70.251% |
Comments by gerihouse for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Buy mit Kursziel 450,0
Kursziel geändert auf 480,0
Kursziel geändert auf 490,0
Kursziel geändert auf 505,0
Kursziel geändert auf 525,0
Kursziel geändert auf 535,0
In the thread Trading Regeneron Pharmaceuticals Inc.
Buy beendet